miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan

miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan

Bibliographic Details
Main Authors:	Schou, Jakob V., Rossi, Simona, Jensen, Benny V., Nielsen, Dorte L., Pfeiffer, Per, Høgdall, Estrid, Yilmaz, Mette, Tejpar, Sabine, Delorenzi, Mauro, Kruhøffer, Mogens, Johansen, Julia S.
Format:	Online
Language:	English
Published:	Public Library of Science 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4062472/

Similar Items

CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab
by: Skougaard, Kristin, et al.
Published: (2014)

Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing
by: Christina Demuth, et al.
Published: (2018-10-01)

MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability
by: Boisen, Mogens Karsbøl, et al.
Published: (2015)

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
by: Kim, Seung Tae, et al.
Published: (2015)

Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer
by: Popovici, Vlad, et al.
Published: (2013)

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours
by: Segelov, Eva, et al.
Published: (2016)

Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer
by: Siena, Salvatore, et al.
Published: (2013)

Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study
by: Burtness, Barbara, et al.
Published: (2016)

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
by: Eng, Cathy, et al.
Published: (2016)

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
by: Seymour, Matthew T, et al.
Published: (2013)

Cetuximab and biomarkers in non-small-cell lung carcinoma
by: Patil, Nitin, et al.
Published: (2012)

Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer
by: Meyerhardt, Jeffrey A., et al.
Published: (2012)

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
by: Spindler, Karen-Lise G, et al.
Published: (2011)

Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab
by: Scartozzi, Mario, et al.
Published: (2012)

Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
by: Giampieri, Riccardo, et al.
Published: (2015)

Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data
by: Buhl, Ida Kappel, et al.
Published: (2016)

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
by: Mekenkamp, Leonie JM, et al.
Published: (2012)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
by: Spindler, K G, et al.
Published: (2013)

Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan
by: Maitra, Radhashree, et al.
Published: (2014)

Comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
by: Tougeron, D, et al.
Published: (2014)

Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
by: Spindler, K-L G, et al.
Published: (2014)

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab
by: Bando, H, et al.
Published: (2011)

KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer
by: Malapelle, U, et al.
Published: (2012)

Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer
by: Barmettler, Hanna, et al.
Published: (2012)

Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer
by: NAKAMOTO, KENTARO, et al.
Published: (2013)

Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report
by: Osumi, Hiroki, et al.
Published: (2013)

Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
by: LAM, KA ON, et al.
Published: (2013)

Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients
by: Gandhi, Anita K., et al.
Published: (2013)

Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status
by: Kato, Junko, et al.
Published: (2016)

Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
by: Hsu, Hung-Chih, et al.
Published: (2016)

p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
by: Kim, Se Hyun, et al.
Published: (2016)

Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma
by: Cheng, Lei, et al.
Published: (2015)

Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients
by: Baas, J. M., et al.
Published: (2015)

Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab
by: Del Re, Marzia, et al.
Published: (2014)

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
by: Folprecht, Gunnar, et al.
Published: (2014)

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial
by: Saridaki, Z, et al.
Published: (2012)

Irinotecan-Induced Dysarthria
by: Dressel, Albertine J., et al.
Published: (2012)

Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study
by: Chen, Kuo-Hsing, et al.
Published: (2016)

Biochip-Based Detection of KRAS Mutation in Non-Small Cell Lung Cancer
by: Kriegshäuser, Gernot, et al.
Published: (2011)

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial
by: Samalin, E, et al.
Published: (2014)